Kornimate/medical-research-clean huggingface dataset:
impact of twice-daily measurement of expired co during hospitalization on smoking

Conditions: Hospitalization; Smoking

Summary: the main objective of this study is to show that the repeated (twice-daily) measurement of expired co during hospitalization helps reduce smoking.

smoking in france represents 25 billion euros per year in care, hospitalizations and drugs and 78000 deaths / year are linked to a pathology attributable to this addiction. in addition, active consumption of cigarettes is a destabilizing factor for chronic respiratory diseases. during hospitalization for acute respiratory illness, evaluation of smoking cessation remains declarative. although stopping advice and possibly nicotine replacement therapy are prescribed, no objective measure of smoking is performed to assess the adequacy of this attitude. this project aims to objectively evaluate smoking during hospitalization by measuring twice daily exhaled co. the impact of this intervention on the duration of hospitalization and smoking 3m after initial admission will also be evaluated. tobacco consumption patterns based on reason for hospital admission and background pathology will be highlighted. secondary objectives include: * to measure the impact of expired co measurement during hospitalization on the smoking status 1 month and 3 months after initial admission. * to determine smoking patterns during hospitalization according to reason for admission and background pathology. * to measure the effect of iterative co measurement on the duration of stays. * to measure and compare the quality of life of patients. * to study the variability of expired co measurements.

Eligibility criteria:
inclusion criteria: * patient hospitalized in pneumology for acute respiratory illness or scheduled hospitalization, for a minimum duration of 48h. * signature of informed consent * patient able to perform all visits and follow the procedures of the study * affiliatedor beneficiary of french social security (national health insurance) exclusion criteria: * subject who can not read and / or write french * expected travel that precludes study completion * patient in palliative care * inability to maintain apnea more than 8 seconds * participation in another clinical trial or administration of an off-label drug within 4 weeks prior to inclusion
supervised asthma medication in schools (sams)

Conditions: Childhood Asthma

Summary: the investigators hypothesize that school-based, direct supervision of daily controller therapy will result in more effective asthma control, as assessed by the asthma control questionnaire than usual care. additionally, as the result of enhanced asthma control and resulting decrease in health care utilization, school-based, direct supervision of daily controller therapy will result in lower cost per quality-adjusted life year (qaly) gained than usual care.

this research is being done to test if children with asthma will have fewer asthma symptoms if they are monitored at school to make sure they take their inhaled steroid medication (ics) every day and take the medication the right way. all of the children with asthma in the school will be asked to participate. in the first year in one-half of the schools, children and school staff will participate in a standardized asthma education program presented by the american lung association (ala). children will have daily monitoring of their inhaled asthma medication. the other half of schools will continue with the usual treatment of children with asthma. in the second year of the study, all schools and children will have the asthma education program and monitoring. parents will be queried quarterly for information about their child's asthma.

Eligibility criteria:
inclusion criteria: * a child with asthma attending a tucson unified school district elementary school selected for the study. exclusion criteria: * no asthma. * not attending a tucson unified school district elementary school selected for the study.
a study to evaluate the long-term efficacy, safety, and tolerability of repeated administration of upadacitinib (abt-494) in participants with crohn's disease

Conditions: Crohn's Disease (CD)

Summary: this is a open-label extension (ole) study designed to evaluate the long-term efficacy, safety, and tolerability of upadacitinib (abt-494).


Eligibility criteria:
inclusion criteria: * participant must have completed study m13-740 through week 52. * if female, participant must be postmenopausal, surgically sterile or on using a birth control method. exclusion criteria: * for any reason participant is considered by the investigator to be an unsuitable candidate * female participant with a positive pregnancy test at baseline or who is considering becoming pregnant during the study. * participant is not in compliance with prior and concomitant medication requirements and procedures throughout study m13-740.

Keywords: crohn's disease efficacy safety tolerability abt-494
metabolomic embryo profiles of obese in vitro fertilization (ivf) patients and their relationship with polycystic ovary syndrome (pco)

Conditions: Infertility; Obesity

Summary: the present study aims to elucidate if there is a metabolomic profile alteration in the embryos of obese women in order to understand if the reduced implantation rate observed in these patients is directly related to this factor. furthermore, the investigators seek to establish if there is any difference between obese women with polycystic ovary syndrome (pco) and without pco. the investigators compare these metabolomic profile embryos with embryos of egg-donation programme.


Eligibility criteria:
inclusion criteria: * bmi \> 30 kg/m2 * age \< 38 years old * non smokers * first ivf cycle (groups 2 \& 3, not control group) * normal uterus (seen by ultrasound) * normal basal hormonal profile(fsh,lh,estradiol,testosterone,androstenedione, insulin, shbg, glucose, amh) * antral follicle count(\> 5 fa for each ovary) * menses every 25-35 days. exclusion criteria: * \ 20 oocytes retrieved after stimulation cycle * estradiol \>3000 pg/ml or progesterone \> 1,5 ng/ml on the hcg day. * \< 2 evolutive embryos in the culture medium.
adapted physical activity for breast cancer her2 positive patient

Conditions: HER2 Positive Breast Cancer

Summary: the purpose of this study is to assess the feasibility of a home-based adapted physical activity during neoadjuvant chemotherapy for her2+ breast cancer.

after the assessment of their physical fitness, a home-based adapted physical activity program composed by aerobic and muscle strengthening exercises will be delivered to each patient. the aim of the intervention is to reach international recommendation in a progressive way during neoadjuvant chemotherapy.

Eligibility criteria:
inclusion criteria: * women \> 18 years old * patient with her2 (human epidermal growth factor receptor 2) positive breast cancer histologically proven, eligible for neoadjuvant chemotherapy and targeted therapy against her-2 * affiliation to the french social security scheme * patient who signed the participation consent before entering the trial * medical fitness certificate for sport exclusion criteria: * diagnosis of a second malignancy in the past 5 years, with the exception of a basal cell skin cancer * metastatic cancer * karnofsky index ≤ 90% * men * pregnant women * significant psychiatric or neurological abnormality * patient deprived of liberty by a court or administrative * contraindication for physical activity * patient unable to complete questionnaires (language barrier) * participation in a clinical trial with the same objective

Keywords: breast cancer her2+ adapted physical activity neoadjuvant chemotherapy
assessment of green dentistry knowledge, attitude and implementation and its association with sociodemographic factors among dental professionals in cairo university.

Conditions: Green Dentistry

Summary: environmental pollution is one of the serious issues causing global warming. each and every individual is responsible for this situation and should make an effort and contribute in keeping the planet green and make it a better place to live for future generations. with escalating contamination of natural resources due to mounting waste generation across industries, including healthcare, the global shift towards ecological sustainability becomes imperative. the aim of this study is to endeavors to evaluate the knowledge, behavior, and implementation of eco-friendly dental strategies among dental professionals (undergraduate and postgraduate dental students) in the faculty of dentistry, cairo university, and its association with sociodemographic data utilizing self-reporting questionnaire in preparation for the implementation of eco-friendly dental practices.


Eligibility criteria:
inclusion criteria: * dental professionals (undergraduate and postgraduate students), faculty of dentistry, cairo university through the academic year 2024-2025. exclusion criteria: * dental students from other universities. * internship dental students.
efficacy of a pragmatic intervention to improve adaptation to context and interlocutor

Conditions: Autism Spectrum Disorder; Developmental Language Disorder

Summary: patients with developmental language disorder (dld) or autism spectrum disorder (asd) have communicational difficulties to adapt their language to context and to interlocutors. these difficulties have long term impacts on education and social life of these patients. speech language therapists (slt) helps child and teenagers with pragmatic and communicational disorders. nevertheless, few research evaluated the efficacy of such interventions. in the present research, the students will do a literature review to identify efficacy intervention's strategies of pragmatic disorders. then, 2 to 5 patients, aged from 8 to 14 years old, with asd or dld and pragmatic disorders, and who haven't intellectual disorder will be recruited. they will come to the faculty of psychology of uclouvain before the beginning of the intervention. in this pretest session, parents will answer questionnaires et children will have tests in order to evaluate their pragmatic abilities (during 30 minutes), like conversations, role plays, communication referential tasks, etc. this evaluation will be video recorded to code pragmatic abilities. then, a group intervention of ten sessions will be proposed (1 session per week, 10 weeks). activities will include role plays, conversations, etc. at the end of the intervention period, a post test session, like the pretest session, will be proposed to evaluate intervention efficacy. the design is multiple study cases. this is the best design to control efficacy of these kind of interventions considering the inter-individual variability of dld and asd patients. this study is original since few research evaluated the efficiency of pragmatic intervention. some studies demonstrated the efficacy of pragmatic intervention in dld and asd patients but theses researches were conducted in english-speaking countries. furthermore, the present research will propose a group intervention, which weren't proposed in the literature to our knowledge (individual intervention). if the group intervention is efficacy, the cost-benefice ratio would be interested.


Eligibility criteria:
inclusion criteria: * diagnostic of asd or dld * pragmatic difficulties exclusion criteria: * intellectual deficiency
trial of iloprost inhaled solution as add-on therapy with bosentan in subjects with pulmonary arterial hypertension (pah)

Conditions: Pulmonary Arterial Hypertension; Ayerza Syndrome; Pulmonary Hypertension

Summary: the purpose of this study is to determine the safety and efficacy of iloprost in subjects that have pulmonary arterial hypertension who are concurrently taking bosentan (tracleer tm).

this is a randomized, placebo-controlled study in subjects with pulmonary arterial hypertension (pah) with an nyha class of iii or iv who are receiving conventional therapy and bosentan. subjects who fulfill the inclusion and exclusion criteria will be randomized to study drug (active or placebo) at a frequency of 6-9 inhalations per day for 12 weeks and will continue conventional therapy and bosentan. at the end of the double-blind phase study, open label iloprost will be provided.

Eligibility criteria:
inclusion criteria: * diagnosis of pah due to pph, connective tissue disease, hiv, or repaired (≥ 1 year) asd, vsd, or pda * nyha functional class iii or iv * on bosentan for at least 16 weeks, with the dose stable (maximum dose 125 mg bid) for at least 8 weeks * age 12-75 years, of either gender * six minute walk distance 100-425 meters at baseline exclusion criteria: * any new long-term treatment for pah added within the last 4 weeks * any therapy with a pde (phosphodiesterase), l -arginine or a prostaglandin, concurrently, or within the last 4 weeks * pah related to chronic thromboembolic disease, portopulmonary disease, or any etiology other than pph, connective tissue disease, hiv, or repaired asd, vsd, or pda

Keywords: step pah iloprost inhalation prostacyclin
effect of a dietary supplement on weight loss and psychological wellbeing in overweight individuals

Conditions: Overweight

Summary: the aim of this randomized, parallel, two-arm, placebo-controlled, double-blind, multicenter clinical trial is to evaluate the efficacy of a dietary supplement on weight loss and psychological well-being in overweight individuals.

the duration of the study will be 6 months during which the investigational product or placebo will be consumed according to the assignment. subjects will be randomized to each of the study arms (consumption of the experimental product or control product).

Eligibility criteria:
inclusion criteria: * adults (age: 30 - 70 yo) * bmi over 25 kg/m2. * subjects who are smokers or non-smokers, but in any case who do not modify their nicotinic habits during their participation in the study. exclusion criteria: * subjects with eating disorders. * bmi less than 25 kg/m2. * history of allergic hypersensitivity or poor tolerance to any component of the products under study. * participation in another clinical trial in the three months prior to the study. * unwillingness or inability to comply with clinical trial procedures. * pregnant woman. * participants with an active daily exercise activity. * subjects whose condition makes them ineligible for the study at the investigator's discretion.
effects of obstructive sleep apnea and/or cigarette smoking on endothelial function

Conditions: Obstructive Sleep Apnea; Smoking

Summary: the hypothesis of this study is that either obstructive sleep apnea (osa) or cigarette smoking (cs) exposure would produce oxidative stress and inflammation leading to endothelial injury, and the combined exposure would be additive or synergistic.


Eligibility criteria:
inclusion criteria: * no acute illness * no hospitalization in past 4 weeks * absence of medical comorbidity such as hypertension, ischemic heart disease, diabetes and hyperlipidemia, renal impairment, vasculitis or raynaud's syndrome, peripheral vascular disease especially buerger's disease, aortic disease (aortic aneurysm or dilatation), cancer, thrombocytopenia, coagulation disorder or other chronic medical illness exclusion criteria: * mentally incapacitated

Keywords: endothelial function
prevention of respiratory infections among children under 3 years of age attending daycare centres

Conditions: Respiratory Tract Infections

Summary: the aim of this study is to evaluate the influence of primary and secondary prevention of respiratory infections in children up to 3 years-old attending daycare.

randomized controlled clinical trial including children up-to 3 years-old who attend daycare centres in o porto. to evaluate the primary prevention of respiratory infections it was created and ministered to children's caregivers an education health session, regarding the prevention of respiratory infections of children, according to caregivers needs. it is known that parental perceptions influence their behaviour in respect to the care of their unwell child. sometimes misunderstandings occurred because parents' expressions of concern or requests for additional information were sometimes perceived as a challenge to the clinicians' diagnosis or treatment decision, which leads to unnecessary and unwanted prescribing of antibiotics. health professionals should provide consistent information that promotes parental self-efficacy in the care of their unwell child. to evaluate the secondary prevention of respiratory infections it was applied to children with signs of upper respiratory infections (rhinorrhea, cough and nasal obstruction) a nasal clearance protocol, developed by guy postiaux. this protocol consists on the application of physiological serum in the nostrils of the child, followed by forced nasal inspiration. the protocol is applied for 3 consecutive days, according to established criteria suggested by postiaux. this intervention is indicated on upper respiratory infections, such as rhinitis or rhinopharyngitis, with large amount of secretions in the upper airway and it is an effective adjuvant for medication. forced nasal inspiration is able to create sufficient gas velocity to act on the pressure of the middle ear, through the eustachian tube, and may have an important role in the prevention of otitis.

Eligibility criteria:
inclusion criteria: children of both genders up to 3 years, born at term, pregnancy without complications, attending day care, residents in oporto, with medical approval for intervention exclusion criteria: children born prematurely, with lower respiratory infections, with chronic neurological, musculoskeletal, cardiac or respiratory disorders

Keywords: upper respiratory tract infections lower respiratory tract infections health promotion respiratory physiotherapy infant
role of inflammatory markers in sepsis

Conditions: Diagnostic

Summary: a diagnostic and prognostic study, in which the expression of cd64 in activated neutrophils and cd64 and il17a regulatory t cells in patients with sepsis will be evaluated as a probable marker for sepsis as a primary objective


Eligibility criteria:
inclusion criteria: * cancer patients admitted to the surgical icu following cancer related surgeries and diagnosed with sepsis exclusion criteria: * refusal of patient or patient guardian to participate. * intraoperative massive blood loss and massive blood transfusion * patients with impaired preoperative kidney or liver function tests
impact of aferbio® on quality of life and chemotherapy toxicity in lung cancer patients

Conditions: Quality of Life; Infection; Drug Toxicity

Summary: the aferbio study will evaluates safety and potential benefit of aferbio® in patients with non-small cell lung cancer undergoing at least a second-line palliative monochemotherapy. aferbio® is a fermented supplement in powder form obtained through biotechnological processes developed in brazil. in this double-blind placebo-controlled randomized clinical trial, participants starting a new palliative regimen will be allocated to aferbio® or placebo. the primary aim will be to compare health-related qol scores among the arms of the study over time.


Eligibility criteria:
inclusion criteria: * age above or equal to 18 years, and below 75 years; * diagnosis of metastatic or recurrent nsclc, beginning second-line palliative mono-chemotherapy treatment; * functional capacity (ecog-ps) grade 0 - 2; * adequate hematological, kidney and liver function, as follows: * total neutrophil count ≥ 1500/μl * platelet count ≥ 100.000/μl * hemoglobin ≥ 9 g/dl * serum bilirubin ≤ 1.5 × upper limit of normal (uln) * patients with confirmed gilbert's syndrome and serum bilirubin ≤ 3 × uln * aspartate aminotransferase (ast), alanine transaminase (alt), alkaline phosphatase ≤ 1.5 × uln, serum creatinine ≤ 1.5 × uln, or creatinine clearance ≥ 50 ml/min based on the cockcroft-gault equation: (140 - age) × (weight in kkg) × (0.85) 72 × (serum creatinine in mg/dl) * absence of any emotional, family-related, sociological, or geographic condition that can potentially hamper adherence to the study protocol and the follow-up schedule; * capacity and willingness to adhere to the study visits and tests, and to adhere to the protocol, according to the researcher's evaluation. exclusion criteria: * tube feeding, gastrostomy- or jejunostomy; * uncontrollable vomiting; * sexually active women of reproductive age, except for those who underwent surgical sterilization (e. g., tubal ligation); * intestinal obstruction or sub-obstruction; * known allergy to any of the components of the investigational product; * malabsorption syndrome or other condition that could interfere with enteric absorption; * history of inflammation of the small or large intestine, previous or currently active (such as crohn's disease or ulcerative colitis); * chronic diarrhea of any cause; * diagnosis of any chronic disease that, in the researcher's opinion, will interfere with the participation in the study; * known diagnosis of hiv -infection; * diagnosis of any chronic disease that changes the immune system and significantly increases the risk of infection; * the need to use g-csf already in the first chemotherapy cycle; * severe neuropsychiatric disease that prevents the patient from completing the study questionnaires, determined at the researcher's discretion.
efficacy maxinom® and maxitrol® in reducing the signs and symptoms of acute bacterial conjunctivitis

Conditions: Bacterial Conjunctivitis; Acute

Summary: the primary objective of this study is to evaluate, through clinical parameters, the effectiveness of your medicine topic maxinom ® (dexamethasone, neomycin and polymyxin b - union chemicals), comparing it to the topical medication maxitrol ® (dexamethasone, neomycin and polymyxin b - alcon ) by the percentage of improvement (sustained response rate) at the end of treatment, among the products studied.

1. evaluation of isolated signs and symptoms during treatment, with a record of individual scores for each parameter and observation 2. statistical comparison of drug safety, by recording qualitative and quantitative parameters related to adverse effects occurring during treatment.

Eligibility criteria:
inclusion criteria: * patients who agree with all study procedures and sign, by his own free will, ic; * adult patients, regardless of gender, ethnicity or social status, with good mental health; * patients who present at screening visit, picture of acute bacterial conjunctivitis diagnosed clinically. exclusion criteria: * patients with clinical diagnosis or suspicion of conjunctivitis due to any process that is not due to bacterial infection, such as infections by fungi, protozoa, viruses and allergic conjunctivitis; * patients with known hypersensitivity to any component of the formulas of the study drugs; * patients with a history or clinical diagnosis of other lesions that may affect the outcome, such as glaucoma, corneal ulcer or scars; * concomitant use of ocular medication other than the study; * pregnant or lactating women; * being or having been treated for any type of conjunctivitis within 15 days and have finished treatment or less than 07 days

Keywords: signs and symptoms of acute bacterial conjunctivitis